| Name | Olsalazine disodium |
| Description | Olsalazine disodium (Dipentum) is bioconverted to 5-aminosalicylic acid (5-ASA) in the colon and has anti-inflammatory activity in ulcerative colitis. |
| In vitro | In nu/nu CD-1 mice with experimental colitis induced by sodium dextran sulfate, daily treatment with Olsalazine (50 mg/kg) led to the bacterial azoreductase cleavage of azo bonds, releasing mesalazine, which is capable of treating colitis. |
| In vivo | In isolated rat ileal and guinea pig ileal mucosa, Olsalazine (less than 2.89 mM) increases the secretion of sodium and chloride ions, while decreasing the absorption of chloride ions. In isolated rat colonic tissues, Olsalazine (less than 11.5 mM) reduces net sodium levels and chloride ion absorption in a dose-dependent manner, and at high concentrations (11.5 mM), it increases potassium secretion. Moreover, in isolated rat jejunum, Olsalazine inhibits the absorption of glucose and lactose. In human intestinal macrophages (IC50=0.39 mM), Olsalazine acts as an effective inhibitor of the chemotaxis of LTB4. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 38 mg/mL (109.76 mM), Sonication is recommended.
DMSO : 50 mg/mL (144.43 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Olsalazine disodium | Olsalazine | Inhibitor | inhibit | IFγ | COX | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Adipic dihydrazide | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Formamide | Hyaluronic acid sodium (MW 20 kDa) | Trometamol | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | NMPA-Approved Drug Library | Anti-Cancer Drug Library |
United States
